ACRX (MC $98M) Cash $72M/ FDA Decision Oct 12 (Blockbuster) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACRX (MC $98M) Cash $72M/ FDA Decision Oct 12 (Blockbuster)

ACRX 1.340

+15.5%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	9/26/2017 10:29:59 AM
	of 8

Only a few days to go untill FDA decision nasdaq.com Near-term catalyst: -- The FDA decision on the Company's investigational product Dsuvia for the treatment of moderate-to-severe acute pain in a medically supervised setting is expected to be announced on October 12, 2017. Dsuvia, formerly known as ARX-04, consists of 30 mcg sufentanil in very small sublingually absorbed tablets that are delivered via a disposable, pre-filled, single-dose applicator. AcelRx estimates that the market potential of Dsuvia in the U.S. will be roughly $1.1 billion.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next